ME תחזית צמיחת רווח נקי למניה לשנה הבאה 23andMe Holding Co

Management crises and conflicts with leadership are weighing on quotes, while the projected net profit growth for 23andMe Holding Co. (ME) demonstrates a level of 0.00, capturing current expectations. Diversification through the development of DNA-data-based drugs mitigates risks, yet the mass exodus of leading bioinformaticians and staff reductions threaten the business's survival. This chart helps track the institutional development trends of 23andMe Holding Co. (ME).
פילוחי מדדים ואנליטיקה של חברת 23andMe Inc. (ME)

Investors must evaluate the competitiveness of 23andMe Holding Co. (ME) through the lens of ESG standard implementation efficiency and genetic data protection. This forward-looking earnings per share growth forecast reflects the consensus estimate of future profitability, enabling a timely identification of business model corrections and preventing the purchase of an overvalued asset amid shifting macroeconomic lags.